Veterinary Medicines

Canigen CHPPi/L, süstesuspensiooni pulber ja suspensioon koertele

Authorised
  • LEPTOSPIRA ICTEROHAEMORRHAGIAE
  • Leptospira interrogans, serovar Canicola, Inactivated
  • Canine parainfluenza virus, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain Lederle, Live
Download as PDF

Product identification

Medicine name:
Canigen CHPPi/L, süstesuspensiooni pulber ja suspensioon koertele
Active substance:
  • LEPTOSPIRA ICTEROHAEMORRHAGIAE
  • Leptospira interrogans, serovar Canicola, Inactivated
  • Canine parainfluenza virus, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain Lederle, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • LEPTOSPIRA ICTEROHAEMORRHAGIAE
    833.00
    million organisms
    /
    1.00
    dose
  • Leptospira interrogans, serovar Canicola, Inactivated
    833.00
    million organisms
    /
    1.00
    dose
  • Canine parainfluenza virus, strain Manhattan, Live
    10000000.00
    50% tissue culture infectious dose
    /
    1.00
    dose
  • Canine parvovirus, strain Cornell 780916, Live
    10000000.00
    50% tissue culture infectious dose
    /
    1.00
    dose
  • Canine adenovirus 2, strain Manhattan, Live
    1000000.00
    50% tissue culture infectious dose
    /
    1.00
    dose
  • Canine distemper virus, strain Lederle, Live
    100000.00
    50% tissue culture infectious dose
    /
    1.00
    dose
Pharmaceutical form:
  • Powder and suspension for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Estonia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • State Agency Of Medicines
Authorisation number:
  • 1362
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Estonian (PDF)
Published on: 9/02/2022
Download